About Fernand Labrie
CDMO - MSH Pharma
FOCUSED ON WOMEN'S HEALTH
and hormone-sensitive cancer for healthy aging worldwide
A low dose (6.5 mg) of intravaginal DHEA permits a local action while maintaining serum estrogens or androgens as well as their metabolites within normal values.
Find out about Intrarosa™
Our goal as a Quebec company
Our main goal is to offer all women in the world, in addition to the treatment of vaginal atrophy, the benefits of effective, physiological and non-negative treatments for all menopausal problems, including hot flashes, bone loss and muscle loss.
Read the news
Lupin Pharma Canada announces the availability of Intrarosa® (prasterone vaginal ovules), a new treatment option in Canada for women with postmenopausal vulvovaginal atrophy
January 25, 2023
Endoceutics Announces Initiation of the Sale and Investment Solicitation Process (SISP)
January 4, 2023
ENDOCEUTICS, INC., AND CERTAIN AFFILIATES (the "Endoceutics Group"), OBTAIN THE ISSUANCE OF AN INITIAL ORDER UNDER THE CCAA
September 28, 2022